{
    "id": 13000,
    "fullName": "PIK3CA E545X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA E545X indicates any Pik3ca missense mutation which results in the glutamic acid (E) at amino acid 545 being replaced by a different amino acid. PIK3CA E545X mutations are \"hotspot\" mutations resulting in increased Pik3ca kinase activity (PMID: 15930273).",
            "references": [
                {
                    "id": 2212,
                    "pubMedId": 15930273,
                    "title": "Functional analysis of PIK3CA gene mutations in human colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15930273"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "E545X",
    "createDate": "10/08/2015",
    "updateDate": "11/05/2019",
    "referenceTranscriptCoordinates": {
        "id": 171759,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179218303_179218305",
        "cDna": "c.1633_1635",
        "protein": "p.E545",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20211,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in progressive disease in a patient with endometrioid adenocarcinoma harboring a PIK3CA E545 mutation, and progressive disease in a patient with serous endometrial adenocarcinoma harboring a PIK3CA E545 mutation (PMID: 31934607).",
            "molecularProfile": {
                "id": 13162,
                "profileName": "PIK3CA E545X"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 2870,
                "name": "endometrial adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17733,
                    "pubMedId": 31934607,
                    "title": "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31934607"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3312,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929).",
            "molecularProfile": {
                "id": 13163,
                "profileName": "KRAS G12X PIK3CA E545X"
            },
            "therapy": {
                "id": 936,
                "therapyName": "Temsirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3726,
                    "pubMedId": 21216929,
                    "title": "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216929"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18719,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33518,
                "profileName": "ERBB2 over exp PIK3CA E545X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18720,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the presence of PIK3CA activating mutations including E542X, E545X, and H1047X correlated with shorter progression-free survival (2.66 months) compared to PIK3CA wild-type or other mutations (4.24 month, HR=1.68, p=0.033) in patients with metastatic Erbb2 (Her2)-positive (amplification or overexpression) breast cancer treated with Poziotinib (HM781-36B) (PMID: 30720867, NCT02418689).",
            "molecularProfile": {
                "id": 33525,
                "profileName": "ERBB2 amp PIK3CA E545X"
            },
            "therapy": {
                "id": 1042,
                "therapyName": "Poziotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16399,
                    "pubMedId": 30720867,
                    "title": "Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30720867"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13162,
            "profileName": "PIK3CA E545X",
            "profileTreatmentApproaches": [
                {
                    "id": 17374,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17371,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17372,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17369,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17367,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17370,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17373,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA E545X"
                },
                {
                    "id": 17368,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA E545X"
                }
            ]
        },
        {
            "id": 13163,
            "profileName": "KRAS G12X PIK3CA E545X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33518,
            "profileName": "ERBB2 over exp PIK3CA E545X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33525,
            "profileName": "ERBB2 amp PIK3CA E545X",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171758,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179218303_179218305",
            "cDna": "c.1633_1635",
            "protein": "p.E545",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171760,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179218303_179218305",
            "cDna": "c.1633_1635",
            "protein": "p.E545",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171759,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179218303_179218305",
            "cDna": "c.1633_1635",
            "protein": "p.E545",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}